AFP and hepatocellular carcinoma: At a willingness to pay at $100,000 per QALY, the incremental cost-effectiveness ratio (ICER) for increased M&T plus the AASLD recommended HCC surveillance strategy with biannual US and AFP ($296/year) would become cost-effective at HCC incidence ≥ 0.55%/year (Fig 2A).